drugset / Trial / NCT04109729
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.
Timeline
- Start
- 2020-09-16
- Primary completion
- 2026-04-28
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Radium-223 dichloride | Other / unclassified | 0.055 mbq/kg | Intravenous |